1175090-19-3

Basic information

• Product Name: methyl 4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)benzoate
• Synonyms: methyl 4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)benzoate
• CAS NO: 1175090-19-3
• Molecular Weight: 293.363
• Mol File: 1175090-19-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: methyl 4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)benzoate(1175090-19-3)
• EPA Substance Registry System: methyl 4-(2-((tert-butoxycarbonyl)(methyl)amino)ethyl)benzoate(1175090-19-3)

Safety Data

• Hazardous Substances Data: 1175090-19-3(Hazardous Substances Data)

Upstream product

• 56161-89-8 4-(2-aminoethyl)-benzoic acid methyl ester-hydrochloride 
• 132690-91-6 4-[2-(tert-butyloxycarbonylamino)ethyl]benzoic acid 
• 74-88-4 methyl iodide 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 

Downstream Products

• 1175090-18-2 4-{2-[(tert-Butoxycarbonyl)(methyl)amino]ethyl}benzoic acid 

Relevant articles and documents

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST

Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

AMIDE DERIVATIVE

The present invention relates to a compound or a pharmacologically acceptable salt thereof that has an excellent antagonistic effect on a neurokinin NK1 receptor, a neurokinin NK2 receptor, and a muscarine M3 receptor and is useful as a therapeutic agent for bronchial asthma, chronic obstructive pulmonary disease, or the like. A compound represented by general formula (I): [wherein R1 represents a hydrogen atom, a C1-C6 alkyl group, or the like; R2 represents a hydrogen atom, a C1-C6 alkyl group, or the like; R3 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like; R4 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, or the like; L1 represents a C1-C10 alkylene group or the like; L2 represents a carbonyl group, a group represneted by the formula -N(R5)-C(=O)-, a group represented by the formula -C(=O)-N(R5)-, or the like; R5 represents a hydrogen atom, a C1-C6 alkyl group, or the like; E represents a phenylene group that may be substituted with 1 to 4 group(s) independently selected from Substituent Group A, or the like; m is an integer of 1 to 4; n is an integer of 0 to 4; p is an integer of 0 to 2; q is an integer of 1 to 10; r is 1 or 2; s is 0 or 1; and Substituent Group A represents the group consisting of a halogen atom, a C1-C6 alkyl group, C1-C6 halogenated alkyl group, or the like] or a pharmacologically acceptable salt thereof.